Completed
PHASE1
INTERVENTIONAL
NCT01502137
Pharmacokinetics of Somatropin in Patients With End Stage Renal Disease Receiving Chronic Haemodialysis
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This trial is conducted in Europe. The aim of this trial is to to compare steady-state total growth hormone (GH) exposure in haemodialysis (HD) patients with that of matched healthy subjects.
Interventions
Name:
somatropin
Type:
DRUG
Description:
Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, patients will receive 8 doses.
Name:
somatropin
Type:
DRUG
Description:
Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, subjects will receive 7 doses.
Primary Outcomes
Measure:
Growth hormone exposure at steady state
TimeFrame:
Description:
Trial Information
NCT ID
NCT01502137
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025